A Borel-Derlon
Overview
Explore the profile of A Borel-Derlon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Negrier C, Ducloy-Bouthors A, Piriou V, de Maistre E, Stieltjes N, Borel-Derlon A, et al.
Vox Sang
. 2017 Dec;
113(2):120-127.
PMID: 29238971
Background And Objectives: A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact in acquired fibrinogen deficiency in real-life medical practice in France. Materials...
2.
Liesner R, Abashidze M, Aleinikova O, Altisent C, Belletrutti M, Borel-Derlon A, et al.
Haemophilia
. 2017 Aug;
24(2):211-220.
PMID: 28815880
Introduction: Nuwiq (Human-cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein fusion. No inhibitors developed in studies with Nuwiq in...
3.
Parcq J, Petersen K, Borel-Derlon A, Gautier P, Ebel M, Vivien D, et al.
Haemophilia
. 2016 Dec;
23(2):319-325.
PMID: 27928886
Introduction: Haemophilia is a major bleeding disorder due to a deficiency of procoagulant factor VIII (type A) or IX (type B). The treatment is substitutive and based on infusion of...
4.
Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, et al.
Haemophilia
. 2016 Jan;
22 Suppl 1:1-24.
PMID: 26728503
Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII...
5.
Gautier P, Repesse Y, Joguet E, Troussard X, Borel-Derlon A, Berger L
Haemophilia
. 2015 Feb;
21(3):e232-e235.
PMID: 25684019
No abstract available.
6.
Grosbois S, Brionne M, de Longcamp A, Gautier P, Kaveri S, Borel-Derlon A, et al.
Haemophilia
. 2012 Dec;
19(2):322-9.
PMID: 23216758
The major complication of the substitutive treatment of haemophilia A (HA) is the development of antifactor VIII (FVIII) antibodies. Most of these antibodies neutralize FVIII procoagulant activity, and are identified...
7.
Rothschild C, dOiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C
Haemophilia
. 2012 Oct;
19(2):281-6.
PMID: 23038998
Immune tolerance induction (ITI) can eliminate factor VIII (FVIII) inhibitory antibodies that appear during FVIII replacement therapy. If first-line ITI fails, switching to a different FVIII concentrate, especially one containing...
8.
Wintz L, Sannie T, Aycaguer S, Guerois C, Bernhard J, Valluet D, et al.
Haemophilia
. 2010 Jan;
16(3):447-54.
PMID: 20088955
The activities of 'expert patients' or 'patient tutors', who help educate their peers, are gaining recognition in the health care system. This study investigates the role played by such patients...
9.
Meunier S, Trossaert M, Berger C, Borel-Derlon A, Dirat G, Donadel-Claeyssens S, et al.
Arch Pediatr
. 2009 Dec;
16(12):1571-8.
PMID: 19960603
During the last decades, long-term prophylaxis has become the gold standard for the treatment of children with severe haemophilia A or B. Prophylactic replacement regimens modify the natural history of...
10.
Bustany S, Gautier P, Lequerrec A, Troussard X, Ollivier Y, Borel-Derlon A
Pathol Biol (Paris)
. 2009 Feb;
57(7-8):536-42.
PMID: 19193498
Acquired von Willebrand syndrome is a rare bleeding disorder, which has been related in various diseases including lymphoproliferative disorders or autoimmune diseases. Its diagnosis is an important step before treatment...